Use of an antibody against the laminin receptor or laminin receptor precursor for the treatment or diagnosis of several cancer types

US7901677B1 · kind B1 · utility

Assignee

• Affimed Therapeutics, AG · DE

Inventors

• Melvyn Little · Büdelsdorf, DE
• Stefan Knackmuss · Plankstadt, DE
• Uwe Reusch · Maikammer, DE
• Sergey Kipriyanov · Heidelberg, DE
• Fabrice Le Gall · Mainz, DE
• Vera Mick · Schifferstadt, DE
• Karin Hoffmann · Schwetzingen, DE
• Peter Röttgen · Ladenburg, DE

Key dates

• Filing date: Apr 5, 2006
• Grant date: Mar 8, 2011
• Expiry date: May 18, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Described is the use of a recombinant antibody comprising a binding site specific for an epitope of the laminin receptor or laminin receptor precursor for the treatment or diagnosis of various cancers, particularly B-CLL. Preferably, this antibody additionally comprises a binding site for at least one particular cell surface antigen.